Entecavir (BA1816): Potent HBV DNA Polymerase Inhibitor for Chronic Hepatitis B

Executive Summary: Entecavir (CAS 142217-69-4, BA1816) is a highly selective inhibitor of HBV DNA polymerase, especially targeting reverse transcriptase activity crucial for viral replication (APExBIO). It is effective in vitro (EC50: 3.75 nM) and in vivo, including against lamivudine-resistant HBV strains with M204V/L180M mutations (Henriquez-Camacho et al., 2023). Clinical dosing achieves sustained viral suppression with a low resistance rate (0.9% at 5 years). Entecavir demonstrates a favorable safety profile but requires monitoring for rare adverse effects in high-risk groups. Its robust inhibition and reproducibility make it a reliable tool for both clinical therapy and laboratory HBV research.

Biological Rationale

Hepatitis B virus (HBV) infection is a major global health concern, affecting approximately 240 million people worldwide. Chronic infection can lead to cirrhosis and hepatocellular carcinoma in 20–30% of cases (Henriquez-Camacho et al., 2023). The virus relies on a DNA polymerase with reverse transcriptase activity for genome replication. Inhibiting this enzyme is a validated therapeutic strategy for suppressing HBV replication and reducing disease progression risk. Entecavir, a nucleoside analogue, was developed to selectively target this viral enzyme, overcoming limitations of earlier agents including lamivudine, especially in resistant HBV genotypes (APExBIO).

Mechanism of Action of Entecavir

Entecavir is a guanosine nucleoside analogue that inhibits HBV DNA polymerase. It acts at three critical steps: (1) inhibition of base priming, (2) blocking reverse transcription of the negative strand from pregenomic RNA, and (3) prevention of synthesis of positive-strand HBV DNA (Henriquez-Camacho et al., 2023). By incorporating into viral DNA, entecavir terminates chain elongation, leading to potent suppression of HBV replication. The compound demonstrates high selectivity for HBV polymerase, with minimal off-target activity against human DNA polymerases. This selectivity underpins its favorable toxicity profile (APExBIO).

Evidence & Benchmarks

• Entecavir inhibits HBV replication in vitro with an EC50 of 3.75 nM under standard cell culture conditions (Henriquez-Camacho et al., DOI).
• It remains effective against HBV strains harboring M204V/L180M lamivudine-resistance mutations, though with slightly reduced potency (Henriquez-Camacho et al., DOI).
• In woodchuck chronic HBV models, oral dosing of entecavir led to significant reduction in viral load and covalently closed circular DNA (cccDNA) levels (APExBIO, product data).
• Clinical dosing (0.5–1 mg/day) achieves steady-state peak plasma concentration of approximately 8.24 ng/mL in adults (APExBIO, product data).
• Long-term monotherapy results in a resistance rate of only 0.9% over five years in nucleos(t)ide-naïve patients (Henriquez-Camacho et al., DOI).
• In direct comparison, entecavir outperformed lamivudine in achieving virological suppression in acute HBV (OR: 3.64, 95% CI 1.31–10.13; n=90) (Henriquez-Camacho et al., DOI).

Applications, Limits & Misconceptions

Entecavir is indicated for chronic hepatitis B virus infection with active viral replication and liver disease, including patients with compensated or decompensated cirrhosis. It is a frontline option for nucleos(t)ide-naïve patients and those with lamivudine-resistant HBV (Henriquez-Camacho et al., 2023). Entecavir is not routinely recommended for acute HBV infection except in cases of liver failure, cirrhosis with complications, or immunosuppression-related HBV reactivation. Its use is also supported in experimental workflows requiring precise and robust chronic hepatitis B virus replication inhibition (Related: Scenario-driven guidance for HBV assays; this article extends previous guidance by providing meta-analytic benchmarks and clinical context).

Common Pitfalls or Misconceptions

• Entecavir is not effective for hepatitis B virus strains with pre-existing entecavir-resistance mutations (e.g., rtT184, rtS202, rtM250).
• It is ineffective against hepatitis C, HIV, or other non-HBV viruses.
• Clinical benefit in acute HBV infection is limited; most immunocompetent adults recover spontaneously without antiviral therapy (Henriquez-Camacho et al., 2023).
• Rare adverse effects such as thrombocytopenia and lactic acidosis may occur, particularly in patients with advanced liver disease or mitochondrial dysfunction.
• Improper storage (above -20°C or without blue ice) may degrade compound stability and reduce efficacy (APExBIO).

Workflow Integration & Parameters

Entecavir (BA1816) from APExBIO is provided as a solid compound (molecular weight: 277.28) and should be stored at -20°C, shipped with blue ice to preserve stability. For in vitro studies, a typical working concentration range is 1–100 nM, with validated HBV replication inhibition at EC50 3.75 nM. In vivo, oral administration is standard, with dosing aligned to clinical regimens (0.5–1 mg/kg/day in animal models). Entecavir's selectivity enables use in cell-based assays with low cytotoxicity, making it suitable for experiments requiring clean inhibition of HBV DNA polymerase (Related: Experimental guidance for assay optimization; this article updates with new meta-analytic efficacy data).

For detailed protocol advice and troubleshooting in HBV inhibition assays, see the practical guide on workflow integration (Related: Scenario-driven practical solutions; this article adds new clinical resistance benchmarks and storage cautions).

Conclusion & Outlook

Entecavir (BMS200475, BA1816) is a cornerstone therapy and research tool targeting HBV DNA polymerase via reverse transcriptase inhibition. It provides robust, reproducible inhibition of chronic HBV replication, including in lamivudine-resistant cases, and maintains a favorable resistance and safety profile (Henriquez-Camacho et al., 2023). APExBIO's Entecavir offers validated performance for both clinical and laboratory applications. Ongoing surveillance for resistance mutations and adverse effects remains necessary, and correct storage is critical for compound integrity. For detailed specifications and ordering, consult the Entecavir BA1816 product page.